Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, leverages the power of artificial intelligence (“AI”) to maximize profits for its growing business-to-business (“B2B”) customer base. “The company offers highly modular, configurable, turnkey, and white-label gaming platforms that are compatible with all major browsers, operating systems and devices. With a focus on maximizing value for partner companies, GMGI integrates AI-powered tools into their systems that facilitate user acquisition, engagement, retention, and monetization… Golden Matrix offers AI-powered solutions that provide a substantial competitive advantage to their partners, enabling them to boost revenues and increase customer retention,” a recent article reads. “‘We provide the tools that change their world,’ said Golden Matrix CEO Brian Goodman in a recent interview. ‘Often people say to me, ‘What makes you different from other systems?… Well, the difference is in our loyalty systems… our products provide these tools, artificial intelligence, loyalty tools, bonus, and free spins.’” To view the full article, visit https://ibn.fm/mK5g9

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.

Technology

Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Friday's trading session at $4.61, up 2.9018%, on 57,191 volume. The average volume for the last 3 months is 57,191 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

• Golden Matrix Group Inc. (NASDAQ: GMGI) - TinyGemsBreaks - Golden Matrix Group Inc. (NASDAQ: GMGI) Leveraging AI-Powered Systems to Maximize Value for B2B Base
• No Debt and a Lot of Money Sets Golden Matrix Group Inc. (NASDAQ: GMGI) Apart as It Sets Sights on ESports Too
• Golden Matrix Group Inc. (NASDAQ: GMGI) Grows Quarterly Net Income by Over 359% Yoy, Sees Margins Widen by Nearly 43%

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

A pair of congressmen has introduced a bipartisan bill that seeks to allow cannabis companies to be listed on national stock exchanges. The bill would also grant the industry access to crucial financial services like banking, solving an issue that has plagued the industry since its inception. Rep. Guy Reschenthaler and Rep. Troy Carter are the cosponsors of the Capital Lending and Investment for Marijuana Businesses (CLIMB) Act. Filed last week, the legislation seeks to allow cannabis and ancillary businesses to access financial services such as checking accounts, cashless payments and loans, something federal law prohibits by threatening action against financial institutions that transact with these businesses. When U.S.-founded cannabis companies are allowed to register on domestic stock exchanges in the same way that entities with roots abroad such as Flora Growth Corp. (NASDAQ: FLGC)  can, the competition in the industry will go up several notches due to the increased flow of capital into different companies.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

• Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
• Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
• Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

• Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
• Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
• Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday's trading session at $0.6594, up 8.0984%, on 285,403 volume. The average volume for the last 3 months is 285,403 and the stock's 52-week low/high is $0.61/$21.45.

Recent News

• Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - New Congressional Measure Will Enable Cannabis Companies to List on Stock Exchanges
• Flora Growth Corp. (NASDAQ: FLGC) Anticipates Continued Growth for Cannabis Operations Under New Colombian Administration
• CannabisNewsBreaks - Flora Growth Corp. (NASDAQ: FLGC) Focused on International Strategy to Reach 'Larger Consumer Base'

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

• No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002 
• Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patients
• The CDC estimates that approximately 1.6 to 3.8 million sports and recreation-related concussions occur annually, for which there is no FDA-approved treatment
• The global concussion market size was valued at $6.8 billion in 2019. This value is expected to rise to $8.9 billion by 2027, growing at a CAGR of 3.6%

Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, has announced positive safety findings from Cohort II of their Phase 1 clinical trial. The company’s Phase 1 trial involves the administration of PRV-002, Odyssey’s novel treatment for concussions, to healthy human subjects. Findings from Cohort II have indicated that the drug is safe and well-tolerated amongst the subjects. Conducted at Nucleus Network, a leading clinical research organization, Cohort II was unblinded and evaluated by the Safety Review Committee. 

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

• PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
  • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
• PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
  • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

• CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
  • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
• Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
  • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Friday's trading session at $0.25, up 2.0408%, on 123,000 volume. The average volume for the last 3 months is 123,000 and the stock's 52-week low/high is $0.11/$0.70.

Recent News

• Odyssey Group International Inc. (OTC: ODYY) - Odyssey Health, Inc. (ODYY) Reports Positive Findings on Phase 1 Clinical Trials of PRV-002 for Concussions
• Odyssey Health, Inc. (ODYY) Taps Military Advisors to Address Target Market for PRV-002 Concussion Drug
• InvestorNewsBreaks - Odyssey Health Inc. (ODYY) Completes Safety Evaluation of Cohort II for Novel Drug to Treat Concussion

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt (NASDAQ: ADTX) recently partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). A recent article reads: “The AditxtScore can be used to provide those tested with important answers to questions like: Are antibodies present? How are these antibodies present – vaccine or natural immune system response? Will this immunity status provide protection from the virus in the future? What is the best approach to creating immunity for that individual?” Regarding the partnership, Kevin Murdock, CEO of Premier Medical Laboratory Services, commented, “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status. With AditxtScore, individuals can make more informed decisions about whether vaccination, boosters or other risk mitigation strategies are the right course of action for them.” To view the full article, visit https://ibn.fm/R5Zzd

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

• Can be made into a product
• Does not require additional hospitalization
• Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

• 8 U.S. patents
• 4 pending U.S. patent applications
• 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

• Autoimmune diseases and Type 1 Diabetes
• Organ transplantation and a method of producing plasmid DNA to prevent immune activation
• Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.

Aditxt Inc. (NASDAQ: ADTX), closed Friday's trading session at $0.1457, up 1.8169%, on 5,402,598 volume. The average volume for the last 3 months is 5.359M and the stock's 52-week low/high is $0.1242/$3.95.

Recent News

• Aditxt Inc. (NASDAQ: ADTX) - BioMedNewsBreaks - Aditxt Inc.'s (NASDAQ: ADTX) AditxtScore(TM) Helping Individuals Make More Informed Decisions
• Virtual Biopsies May Revolutionize Procedures Used in Heart Transplants
• BioMedNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Pursuing Strategy Against COVID-19, Immune System-Related Maladies

Kronos Advanced Technologies Inc. (OTC: KNOS)

The QualityStocks Daily Newsletter would like to spotlight Kronos Advanced Technologies Inc. (OTC: KNOS).

Kronos Advanced Technologies (OTC: KNOS), a revenue-generating product development and production company that has significantly changed the way air is moved, filtered and disinfected, stands to benefit from the new initiative by the Biden administration to improve indoor air as part of its latest response to the ongoing coronavirus pandemic. “The Biden administration and Congress have provided hundreds of billions of dollars in federal funds that can be used in schools, public buildings and other settings to improve indoor air quality,” reads a recent article that contains excerpts from a recent White House fact sheet. “Kronos Advanced Technologies stands to benefit from the new initiative. The company’s Kronos AIR 5G(R) Air Purifiers are some of the most powerful and effective air purifiers available today. The devices, which come in three models, feature Kronos’ own patented, medical-grade technology, which has been tested and confirmed as the most effective clean-air solution on the market… Unlike traditional HEPA systems that collect pollutants on filters, which can grow mold and bacteria with time, Kronos’ patented technology collects and eliminates harmful particles, depositing them on easy-to-clean collecting plates.” To view the full article, visit https://ibn.fm/bw7Uh

Kronos Advanced Technologies Inc. (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings.

Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of a traditional HEPA filter. Kronos® not only collects but destroys air pollutants. Kronos® AIR 5G® Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles.

Kronos® devices operate silently using nanotechnology to remove 100% of pollutants in a 400ft2 room (up to the whole house) and replenishes the room with pure, clean air every 15 minutes. Indoor household air is often four times more polluted than outdoor air, and Kronos air purifiers act like bionic lungs for the home and protect the people in it.

Unlike traditional HEPA systems that collect pollutants on filters which can, over time, grow mold and bacteria, Kronos’ patented technology destroys and eliminates all manner of harmful particles and deposits them on easy-to-clean collecting plates. This reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month.

The Kronos® AIR 5G® Air Purifier destroys and eliminates dust, allergens, bacteria, and even viruses. The AIR 5G® has been third party lab tested and confirmed to kill 99.87% of influenza virus in one hour.

The patented system’s five step process starts with a pre-filter screen that filters and collects hair, pet dander, etc. The air is then pulled through emitter wires which create a 30,000-volt electro field that zaps dangerous particulates. In the ionic field, charged particles are destroyed, killing bacteria and pathogens. The particles are then captured on collecting plates, removing dangerous toxins from circulation. The collecting plate is easily cleaned and reused without buying new filters. The catalytic layer is the final step in the purification process, removing odors and keeping the air fresh and pure. The AIR 5G® has Smart Control Auto Mode, which measures and displays the air quality in the room and self-adjusts fan speed based on how dirty the air is in the room. There’s also an AIR 5G® Smart App that displays the real time Air Quality Index and acts as a remote control.

The Kronos® AIR 5G® Air Purifier is offered in three models:

• Kronos® AIR 5G® X3 air purifier combines powerful patented TPA® technology with a compact form factor up to six times smaller than other air purifiers, with washable and reusable filters.
• Kronos® AIR 5G® X5 thoroughly wipes out dust, smoke, dander, bacteria, pollen, viruses, odors, germs, and more from the air, delivering the healthiest breathable air possible. It was developed for some of the world’s most polluted areas and is now available for use in the home. It runs completely silently, passing through five stages of purification to guarantee the cleanest possible air in homes or offices.
• Kronos® AIR 5G® X8 delivers maximum power, more than doubling the capacity and efficiency of the Kronos X5, with CADR speeds of up to 470 CFM – enough to clean a 1,000ft2 room in just 20 minutes.

Kronos also offers the Kronos Car Air Purifier, the most advanced car air purifier with Kronos’ patented TPA® technology, and FitAir, the best personal air purifying solution that brings clean air anywhere by cleaning within 25ft2 of personal space at an airflow rate of 3x per hour.

Market Overview

The global air purifier market was valued at $10.38 billion in 2020 and is expected to reach $21.15 billion by 2027, achieving a CAGR of 10.7% over the forecast period, according to Brandessence Market Research. The market is primarily driven by the increasing concerns about both outdoor and indoor air pollution, coupled with the associated health problems.

Air pollution is one of the most prevalent concerns, due to worsening environmental condition. According to Health Effect Institute, it accounts for 4.9 million to 8.8 million deaths worldwide each year. Furthermore, as most of our time is spent is indoors, indoor air pollution remains a serious concern to individuals, as well as regulatory agencies. Particles like PM 2.5 can enter indoors through a wide range of sources including car engines, fireplaces, and coal- or natural gas and the infiltration of ambient particulates in urban areas. Even in the absence of solid fuels, indoor ventilation can build up PM 2.5 particles to a greater extent than in outdoor environments. Growing demand for portable air purification filters and systems in urban areas, increased advancements to catch key particulates like coronavirus, and increased regulatory measures to ensure safe environments for professionals in the industrial sector remain leading drivers of growth in the air purifier market.

Poor indoor air quality can cause fatigue, headache, and irritation of the eyes, throat, lungs, and nose, which can have a negative impact on worker productivity. Some air contaminants can cause asthma and other respiratory diseases.

Air purifier adoption is increasing rapidly in the U.S. to minimize health issues caused by poor air quality. Strict air quality standards, guidelines, and regulations in the U.S. are expected to have a positive impact on the market. For instance, the New Jersey Indoor Air Quality standard, NJAC 12:100-13 (2007), sets guidelines and standards related to indoor air quality during working hours in public employee-occupied buildings.

Key manufacturers are focusing on acquisitions and mergers to expand their geographical reach and strengthen their position in the market.

Management Team

Michael Rubinov, President and Head of Business Development

A seasoned hi-tech executive with 25 years of global business experience, Mr. Rubinov has served in various positions in sales, marketing, channel development and partner management. He has worked for large and global organizations such as Intel, NICE Systems, and Boeing (Defense and Security), as well as for start-up companies like Dialogic and Remunera International SA. He was appointed President and Head of Business Development of Kronos Advanced Technologies Inc. in February 2020. Mr. Rubinov holds an MBA, an MS Computer Sciences, and a BS Electrical Engineering.

Joseph L. Florence, Chief Operational Officer & CTO

A dynamic skilled leader in all aspects of business formation, evaluation, and execution, Mr. Florence brings a unique combination of Fortune 100 company experience with a lifetime of entrepreneurial experience to the Kronos team. He is a gifted visionary, possessing the unique ability to see future opportunities and make timely strategic adjustments and is naturally gifted at seeing unrecognized risk and overlooked opportunities. Mr. Florence has a proven track record of transforming companies to better align people, processes, and technologies to meet strategic goals and business metrics resulting in increased market share and profitability.

Kronos Advanced Technologies Inc. (OTC: KNOS), closed Friday's trading session at $0.0134, up 1.5152%, on 18,147 volume. The average volume for the last 3 months is 18,147 and the stock's 52-week low/high is $0.01/$0.064.

Recent News

• Kronos Advanced Technologies Inc. (OTC: KNOS) - InvestorNewsBreaks - Kronos Advanced Technologies Inc. (KNOS) Set to Benefit from Renewed Focus on Indoor Air Quality
• Kronos Advanced Technologies Inc. (KNOS) Offers Best Air-Purification Devices in Growing Market
• Kronos Advanced Technologies Inc. (KNOS) Has Impressive History of Commitment to Air Quality

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

• The current Texas heatwave and the demand on the power grid have reached record numbers, driving more consideration for renewable energy sources like wind and solar power
• Correlate Infrastructure Partners Inc. offers a complete suite of clean energy assessment solutions for commercial real estate to find the appropriate avenue for incorporating more energy-efficient capabilities
• The global renewable energy market, valued at $881.7 billion in 2020, is driven by the need to reduce carbon emissions and other greenhouse gasses

As unusually high temperatures sweep across the Southwestern U.S., especially Texas, new records for electricity demands are being reached. Texas grid operator ERCOT projects have recorded several peak days since the heatwave began in Texas, many of which surpass 75 gigawatts and have smashed records established in 2019. Thankfully, the state’s electric grid has so far been able to successfully meet high electricity demand, unlike previous years when extreme weather events created vulnerable situations that included blackouts (https://ibn.fm/k1EfM). Correlate Infrastructure Partners (OTCQB: CIPI), a purpose-built energy use optimization company pursuing green utilities solutions for the commercial real estate industry, is innovating the industry with the mission of sustainability and the kickback of increased net operating income. “Correlate Infrastructure Partners is making energy management and procurement transparent and cost-effective as we digitize the process that has been archaic for way too long. We are excited to be at the forefront of an industry that is at an inflection point, and we are eager to begin working to change the way commercial real estate owners optimize energy assets,” a recent article quotes CEO Todd Michaels as saying. “The company uses proprietary data analysis and concierge services to help facilities owners and construction professionals evaluate and improve their energy usage footprints, providing the necessary information to work through what Utah’s Clean Energy authorities branded a ‘net-zero learning curve.’” To view the full article, visit https://ibn.fm/EKr8a

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Friday's trading session at $1.1, even for the day. The average volume for the last 3 months is 27 and the stock's 52-week low/high is $0.30/$3.25.

Recent News

• Correlate Infrastructure Partners Inc. (OTCQB: CIPI) - GreenEnergyBreaks - Correlate Infrastructure Partners Inc. (CIPI) Making Energy Management, Procurement Transparent and Cost-Effective
• Green Energy Helping Texas Power Grid Withstand Unusually High Demand; Correlate Infrastructure Partners Inc. (CIPI) Supplying Cost-Efficient Solutions for Renewable Energy Options
• Correlate Infrastructure Partners Inc. (CIPI) Collaborates with Abundant IoT for the Correlate Portfolio Health Program Launch

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF)

The QualityStocks Daily Newsletter would like to spotlight AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF).

As the coronavirus pandemic raged on and millions of people across the world became infected with the virus, it became clear that for some people, the symptoms of COVID did not abate after a few weeks. Rather, these individuals experienced a variety of symptoms for months after their initial diagnosis, a phenomenon that was soon dubbed long COVID. Additionally, it seemed like women had a heightened risk of experiencing long COVID than men. This is despite the fact that previous research had shown men’s immune systems to be weaker against the coronavirus compared to women. These clinical complications resulting from how the immune systems of different people respond to the same threats is an area of focus for entities such as AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF), which would like to find remedies that help patients recover fully from viral infections.

As the coronavirus pandemic raged on and millions of people across the world became infected with the virus, it became clear that for some people, the symptoms of COVID did not abate after a few weeks. Rather, these individuals experienced a variety of symptoms for months after their initial diagnosis, a phenomenon that was soon dubbed long COVID. Additionally, it seemed like women had a heightened risk of experiencing long COVID than men. This is despite the fact that previous research had shown men’s immune systems to be weaker against the coronavirus compared to women. These clinical complications resulting from how the immune systems of different people respond to the same threats is an area of focus for entities such as AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF), which would like to find remedies that help patients recover fully from viral infections.

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful collaborations in the life science industry. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system.

AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (SAB), experienced staff, and executive leadership to drive its product pipeline. AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine Merchant™, an enterprise marketing platform built to enable consumers to have access to novel therapeutic approaches to human nutrition, endemic diseases, and neglected chronic related co-morbidities. The company also expects to generate revenue from toll processing and government procurement of its products that address malnutrition and related health issues.

AREV is focused on innovations in biomedicine and maintains a significant footprint in clinical human nutrition utilizing proprietary protein blends and terpenes, complimented with vitamins and minerals. The company has utilized its expertise to design and deliver innovation in therapeutic interventions using its exclusive botanical, fungi and marine compounds to address medical conditions driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV uses its proprietary extractions allowing characterizations from botanical and marine sources in therapeutic foods and medicines that comprise its development pipeline.

Development of AREV’s pipeline is fostered by collaborations with academic centers, clinical research organizations and government institutions committed to facilitating discovery of promising new clinical approaches presented in peer reviewed journals. AREV operates under the guidance of its SAB and a growing number of strategic collaborations with CROs and academic research centers, including the Linus Pauling Institute at Oregon State University.

AREV is a member of both BIOTECanada and The Biotechnology Industry Organization (BIO):

• BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the diverse nature of Canada’s health, industrial and agricultural biotechnology sectors.
• BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and 30+ countries.

Products

AREV’s end-product and target categories include therapeutic interventions, botanical drugs, ready-to-use therapeutic food (RUTF), enteral nutrition formulas and early-stage small molecule antiviral therapeutics demonstrating novel mechanisms of action.

Wright and Well Branded Line

Wright and Well Branded Line is the company’s branded line of therapeutic cannabinoid and terpene-based formulations. The topical line includes solutions for burns, wounds, skin disorders and muscle relief, as well as a lubricant for intimacy. The oral line addresses inflammation, heart health, high blood pressure and viral infections. These products are currently produced at CBD99, a licensed processor in Sandy, Oregon. The company also has a strategic relationship with a Canadian licensed hemp and cannabis processor in Vancouver, British Columbia.

SUS-TAINN™

The company’s products in the RUTF category are branded under SUS-TAINN™ (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs). SUS-TAINN™ is the flagship line of products stemming from AREV’s collaboration with Voynich Biosciences.

RUTFs like SUS-TAINN™ are the cornerstone to international famine response and currently represent more than 20 percent of public health commodity procurement spending. SUS-TAINN™ is purchased by agencies ranging from the U.S. Department of State AID for International Development to the World Food Program and is distributed by an increasingly substantial number of non-governmental organizations.

RESTORE™

The company’s enteral nutrition product is branded as RESTORE™. For patients experiencing caloric compromise, enteral nutrition, a liquid form of nourishment, is often required. RESTORE™, the initial enteral formulation from AREV, is based on organic plant nutrition for patient populations who have demonstrated overt clinical need for rational enhanced caloric intake and micronutrient supplementation.

RESTORE™ provides a proprietary blend of high-quality proteins, antioxidants, minerals and proven anabolic agents, combined with pre- and probiotics. The company plans to submit for Medicaid formulary inclusion and reimbursement designations in various jurisdictions characterized by the Ryan White CARE Act during the second half of 2022.

REV-I1™

REV-I1™ is the company’s small molecule drug discovery model for phytomedicinalization, based on advanced computational characterization and next generation affinity selection that affords new opportunities in HIV antiretroviral research. REV inhibition offers a critical approach to inhibiting HIV replication and addressing viremia in highly conserved sanctuary regions.

Phytomedicinal therapeutic discovery and development offer clinically viable approaches to a wide range of scientific challenges that currently elude successful contemporary interventions. A cornucopia of diverse validated compounds allows AREV to explore a distinguished range of promising approaches that are in stages of pre-clinical validation. Combining AREV’s versatile extraction capability with highly sensitive analytical techniques (LC-MS, MS-MS) is expected to allow new medicinal chemistry to be identified and characterized, leading to therapeutic candidates in the company’s commercial drug discovery platform.

Market Overview

A report from Verified Market Research valued the global plant protein market at $29.4 billion in 2020 and forecast that it could surpass $162 billion by 2030, which would make up 7.7% of the global protein market, according to a report released in August by Bloomberg Intelligence.

The RUTF market was valued at $363.72 million in 2019 and is projected to reach $807.89 million by 2027, growing at a CAGR of 10.5% for the forecast period. The market is primarily driven by the efforts of governments and non-governmental organizations to reduce the rate of severe acute malnutrition. Moreover, changing trends and growing developments related to diet-related deficiencies, as well as increasing incidences of famine and disasters, are likely to fuel the growth of the RUTF market in the near future, according to the report.

Management Team

Michael Withrow is the founder, chairman and CEO of AREV. He is a successful natural products and technology entrepreneur with more than 25 years of experience. He has started and sold companies and has worked with companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. He has also served as president and CEO of a specialty cannabis technology company.

Kevin Phelps, CPA, is a director at AREV. He is CEO and president of Immune Therapeutics Inc., a bio-pharmaceutical company. He began his career with Price Waterhouse before joining Eastman Kodak Company as part of an executive team that successfully spun out the Bio Products Division into Genencor International Inc., an international industrial bio-chemicals company. He later joined Trillium Group, a regional private equity firm, as a partner, where he served on behalf of the firm as CFO of Vaccinex Inc., a vaccine development company, and chairman of AccuMed Inc., a medical device company. He has served as Chairman of Oyagen, a biotech that over the past decade has developed drug discovery methods that have enabled it to explore vulnerabilities in HIV, Ebola and coronaviruses.

Denby Greenslade is corporate secretary and interim CFO at AREV. She has served as corporate secretary and director for several companies in the mining, biotech and IT industries and has more than 15 years of corporate secretarial, corporate governance, and securities regulation experience. She graduated from Simon Fraser University with a Bachelor of Arts in Communication.

Allan Echino is a director at AREV. He was a founder and director of Corlac Resources, an oil producer, and Calroc Industries, an oil service company based in Alberta. Mr. Echino arranged funding for a licensed producer in the cannabis sector and quickly learned the business and health benefits of cannabis and mushrooms.

Mel Maxwell is a director at AREV. During his 40-plus year career, he has founded six companies. His degrees in business and computer science initially took his career toward IT ventures that entailed software development, IT consulting, e-commerce solutions, real estate development, pathogen remediation solutions and wholesale vehicle aggregation. He finds continued enjoyment in consulting with other businesses and entrepreneurs.

Scientific Advisory Board

Roscoe M. Moore, Jr., DVM, MPH, PhD, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms as chairman of the company’s scientific advisory board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (IHV) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV.

Dr. Moore served with the United States Department of Health and Human Services (HHS) and was responsible, for the last 12 years of his career, for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service, entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (CDC), where he also served as an epidemic intelligence service officer.

Robert Melamede, PhD, received his doctorate in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab, where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes. Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs. He co-founded Cannabis Science Inc., a public company, retiring as the company’s chief executive in 2014. Dr. Melamede continues his innovative research in the private sector.

Harold Smith, PhD, is the founder, CEO, and president of Oyagen Inc., a biotechnology company developing therapeutics for various disease states, including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology.

Richard Van Breemen, PhD, is a Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences of the College of Pharmacy at Oregon State University. His research interests include cancer prevention by dietary antioxidants and prostate cancer prevention by the carotenoid lycopene, mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to assess drug metabolism, toxicity and bioavailability. Dr. Van Breemen made The Analytical Scientist’s Power List in 2020 and 2021. His work in biomedical mass spectrometry earned him an initial spot, and he clocked in the Top 100 analytical scientists from around the world on the Power List in 2021.

Dr. Blake Hawley is the founder & CEO of Motega Health Inc. Dr. Hawley has worked in animal health, pharma and food across 23 countries and four continents. He holds an MBA from KU and his doctorate in veterinary medicine and zoology degrees from NC State. He serves on multiple non-profit advisory boards, including the KU MBA Advisory Board. Dr. Hawley is a 2017 graduate of Pipeline Entrepreneurs and a graduate of the Village Capital Agricultural 2016 Entrepreneur Cohort.

Dr. Hawley previously served as the General Manager of Australasia; Regional General Manager of Russia and Central Eastern Europe (consisting of 22 countries); and Managing Director of the United Kingdom and Ireland for Hill’s Pet Nutrition, a division of Colgate-Palmolive. His experience includes 10 years of profit and loss responsibilities in these territories, with consistent double-digit annual revenue growth in each of the 10 years. He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley also has background in e-commerce, data analytics, and social media and most recently served as Worldwide Director of Global Digital for Hill’s Pet Nutrition.

Uma Dhanabalan, MD, MPH, FAAFP, MRO, CMS, advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey, with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master’s degree in public health from Harvard’s School of Public Health in Boston, Massachusetts, and continued her training at Harvard in occupational and environmental medicine.

Special IP Advisor

Douglas Sorroco practices in all areas of intellectual property law including patent, trademark, copyright, technology, and e-commerce and assists clients with intellectual property matters requiring litigation, licensing, technology counselling and complex transactions.

Mr. Sorroco is ranked in Band 1 (the top band) for intellectual property law by the highly regarded Chambers USA: America’s Leading Lawyers for Business 2021, and he was selected for inclusion in The Best Lawyers in America® 2022 for Litigation – Intellectual Property, Litigation – Patent, Patent Law and Technology Law. In 2021, Best Lawyers named him the Oklahoma Lawyer of the Year for Technology Law. In 2021, Managing Intellectual Property continued to rank Doug as an IP Star. Mr. Sorroco was selected for inclusion in Oklahoma Super Lawyers 2021 and was also selected by attorney peers for inclusion in Oklahoma Super Lawyers – Rising Stars Edition (2010).

AREV Life Sciences Global Corp. (OTC: AREVF), closed Friday's trading session at $0.1008, even for the day. The average volume for the last 3 months is 105 and the stock's 52-week low/high is $0.054/$0.32616.

Recent News

• AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) - New Research Says Immune Cell Proliferation May Be Associated with Multiple Sclerosis Onset
• Diseases Suppressed by COVID-19 Restrictions Reemerge in Peculiar Ways
• AREV Life Sciences announces acceleration of the clinical development of SUSTAINN, as further predictions of global famine increase demand for Ready to Use Therapeutic Foods (RUTF)

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

• LQwD currently has Lightning Network nodes in 17 countries with a goal of 24 by the end of Q4 2022
• The current LQwD nodes have already processed over 10k transactions, and the number is climbing
• The global cryptocurrency market was valued at US $1.49 billion in 2020. The market is projected to reach US $4.94 billion by 2030, growing at a CAGR of 12.8%

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF) continues to move forward with its endeavors on the Bitcoin Lightning Network. The company currently has active nodes spanning 17 countries, including the U.S., Ireland, India, Germany, Brazil, Hong Kong, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, France, Canada, England, and Japan. These nodes range in capacity from 0.050000000 BTC to 5.700269470 BTC. The longest running node within the company’s selection is US-West, released in November 2021. 

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Friday's trading session at $0.08925, even for the day, on 8 volume. The average volume for the last 3 months is 8 and the stock's 52-week low/high is $0.0754/$0.672.

Recent News

• LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Plans to Reach 24 Countries by Q4 2022
• InvestorNewsBreaks - LQwD Fintech Corp. (TSX.V: LQWD) (OTC: LQWDF) Expands Coverage Routes by Adding 17 New Routing Nodes
• CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Scaling Capacity on Lightning Network

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

• Cepton aims to increase active engagements and initiatives with automotive OEMs with a newly opened office located in Metro Detroit
• CPTN was added as a member to the Russell 3000(R) Index on June 27, 2022
• Cepton is a leading developer of lidar solutions for automotive (ADAS/AV), smart cities, smart spaces, and smart industrial applications
• CPTN management aims to make lidar a standard safety feature in the cars of today and the key component in the autonomous vehicles of the future

Cepton (NASDAQ: CPTN) plans to utilize its new corporate office in Metro Detroit (Troy, MI) to widen its growing engagements and initiatives with automotive original equipment manufacturers (“OEMs”) (https://ibn.fm/Bpu1g). The Silicon Valley innovator and leader specializes in high-performance Micro Motion Technology (MMT(R)) lidar solutions that enable reliable, scalable, long-range, high-resolution 3D perception for smart applications.

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

• Reliability – The durable design uses common, easily attainable materials.
• Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
• Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
• Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Friday's trading session at $1.54, off by 1.2821%, on 116,416 volume. The average volume for the last 3 months is 101,264 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

• Cepton Inc. (NASDAQ: CPTN) - Cepton, Inc. (NASDAQ: CPTN) Announces Plans to Boost OEM Initiatives with New Center of Excellence in Detroit and Inclusion in Russell 3000(R) Index
• InvestorNewsBreaks - Cepton Inc. (NASDAQ: CPTN) Expands Collaboration Efforts with Tier 1 Supplier of Automotive Lighting Equipment
• Cepton, Inc. (NASDAQ: CPTN), a Leader in Lidar, Continues to Execute on its Core Strategic Milestones Across Automotive & Smart Infrastructure

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Anyone who has used DMT (N, N-dimethyltryptamine) knows that it is a powerful hallucinogen that can induce immersive hallucinations in only a few minutes. The drug’s effects are similar to those of other psychedelics, including psilocybin mushrooms and LSD. Now that psychedelics are seeing a resurgence in popularity, researchers have been interested in how these drugs can impact mental health. According to a new study published in the “Nature” journal, DMT may have the potential to treat depression. The researchers’ objective was to see whether administering DMT would have any effect on patients with depressive symptoms. Researchers discovered that patients with treatment-resistant major depressive disorder who underwent DMT treatment had significantly reduced depressive symptoms. Furthermore, they found the drug to be “mostly safe and well-tolerated.” Many other companies, including Silo Pharma Inc. (OTCQB: SILO), are also undertaking their own R&D in order to develop mental-health treatments from a variety of psychedelic compounds; it looks like the future is bright for these once-ostracized compounds.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Friday's trading session at $0.11, off by 0.090827%, on 76,310 volume. The average volume for the last 3 months is 76,310 and the stock's 52-week low/high is $0.09/$0.2678.

Recent News

• Silo Pharma Inc. (OTCQB: SILO) - New Report Says Smoking Amplifies Schizophrenia and Depression Risk
• What Investors Interested in Psychedelics Need to Focus on Regarding IP Issues
• InvestorNewsBreaks - Silo Pharma Inc. (SILO) Announces Expansion of License Agreement and Patent Portfolio

SPYR Inc. (OTCQB: SPYR)

The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.

Products

The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

• The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
• The HomeKit Secure Video Camera with iCloud Storage
• The Multipurpose Sensor with Alarm
• The Environment and Motion Sensor
• The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Friday's trading session at $0.0257, up 35.2632%, on 4,236,384 volume. The average volume for the last 3 months is 4.136M and the stock's 52-week low/high is $0.018/$0.09935.

Recent News

• SPYR Inc. (OTCQB: SPYR) - InvestorNewsBreaks - SPYR Inc. (SPYR) Shares GeoTraq Update
• Introducing SPYR Technologies' Acquisition, GeoTraq
• InvestorNewsBreaks - SPYR Technologies (SPYR) Announces Strategic Engagement of Integrity Media

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Friday's trading session at $1.08, up 5.8824%, on 61,831,850 volume. The average volume for the last 3 months is 61.832M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Expects to Report >$61M in Cash, Cash Equivalents After Significantly Strengthening Balance Sheet
• To Lease or Buy an EV: The Pros and Cons
• Mullen Automotive Inc. (NASDAQ: MULN) Retrofits Existing Facility to Move EV Battery Pack Production In-House